Zhangjiang's biopharmaceutical industry shows rapid growth

The 2022 Zhangjiang Life Science International Innovation Summit kicked off on Nov 15. At the event, the 2022 Zhangjiang biopharmaceutical innovation index was released and it scored 117.33 this year, up 4.81 percent.

Biomedical research and development in Zhangjiang has yielded fruitful results, with seven new Category I medicines and seven new innovative medical devices being created this year.

In 2021, there were 10 newly listed science and innovation enterprises, which brought the total number to 29, an increase of 52.64 percent year-on-year, and accounted for 21 percent of the national total.

At the event, the first edition of the Zhangjiang Life Science Industry New Prominent presented the rising star award to 10 workers who have made great contributions to the biomedical development this year, and to 10 enterprises that have showed remarkable growth.

The first edition of the Zhangjiang Life Science Industry New Prominent gets underway at 2022 Zhangjiang Life Science International Innovation Summit. [Photo/WeChat account: gh_01c6f7b4cf3d]

According to Shi Qian, director of the Shanghai Institute for Science of Science, the innovation unfolding in Zhangjiang is based on three global innovation networks, which consist of a global innovative network, a global innovation cooperation network and a global innovation trade network.

Currently, there are more than 4,000 scientists working in Zhangjiang Hi-Tech Park, with 184 ranking in the top 1 percent in the world for scientific research, and 1,422 ranking in the top 10 percent.